Alnylam Pharmaceuticals Inc (ALNY) — Capital Reinvestment Ratio
Alnylam Pharmaceuticals Inc (ALNY) has a Capital Reinvestment Ratio of 0.14x as of December 2025, meaning it reinvests 0% of its operating cash flow ($163.56 Million) in capital expenditures ($23.29 Million). Check ALNY goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Alnylam Pharmaceuticals Inc Capital Reinvestment Ratio (2007–2025)
This chart tracks Alnylam Pharmaceuticals Inc's Capital Reinvestment Ratio across 4 annual periods. For the full cash flow conversion analysis, see Alnylam Pharmaceuticals Inc cash conversion from operations.
Annual Capital Reinvestment Ratio for Alnylam Pharmaceuticals Inc (2007–2025)
Year-by-year Capital Reinvestment Ratio for Alnylam Pharmaceuticals Inc from 2007 to 2025. See Alnylam Pharmaceuticals Inc (ALNY) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.11x | $524.08 Million | $58.70 Million | ▼ -81.2% |
| 2023 | 0.60x | $104.16 Million | $62.21 Million | ▲ +263.4% |
| 2008 | 0.16x | $65.49 Million | $10.76 Million | ▲ +314.7% |
| 2007 | 0.04x | $196.52 Million | $7.79 Million | — |